Semaglutide Dosage: The Full Schedule Explained (2026)

Semaglutide dosing at a glance

Each form of semaglutide has its own FDA-approved escalation schedule — a slow step-up that exists to limit side effects. Here is the summary; the detail and the missed-dose rules follow below.

• Wegovy (weight management, weekly injection): starts at 0.25 mg and steps up to a 2.4 mg maintenance dose over at least 16 weeks; 1.7 mg is an alternative maintenance dose, and a 7.2 mg strength (Wegovy HD) is a step-up above 2.4 mg.
• Oral Wegovy (weight management, daily tablet, approved 2026): 1.5 mg up to a 25 mg maintenance dose over 12+ weeks, taken on an empty stomach.
• Ozempic (type 2 diabetes, weekly injection): 0.25 mg up to a 2 mg ceiling; maintenance is usually 1 mg or 2 mg, guided by blood sugar.
• Rybelsus (type 2 diabetes, daily tablet): 3 mg up to a 14 mg ceiling, taken on an empty stomach 30 minutes before food.
• Compounded semaglutide (vial + syringe): the dose is drawn in units and depends on the vial concentration — it requires a prescriber and a 503A pharmacy.

The Wegovy dose escalation schedule, step by step

Wegovy is the FDA-approved semaglutide formulation for chronic weight management in adults with a BMI of 30 or above, or a BMI of 27 or above with at least one weight-related condition (high blood pressure, type 2 diabetes, or high cholesterol). The dose escalation schedule exists for one reason: giving your body time to adjust to the medication and minimizing gastrointestinal side effects like nausea and vomiting, which are the most common reasons patients reduce or stop the drug.

According to the FDA prescribing information, if you cannot tolerate a dose during escalation, your prescriber may delay the next step by four weeks rather than push through. This is not a failure — it is an explicit option built into the labeling. The goal is to reach the maintenance dose, not to hit a calendar target.

2.4 mg is the standard maintenance dose, and the label also recognizes 1.7 mg for people who cannot tolerate it. Most patients are titrated to 2.4 mg, but if side effects at that level are intolerable, a prescriber may drop back to 1.7 mg. If 1.7 mg still causes persistent issues, discontinuation may be considered. The 0.25 mg, 0.5 mg, and 1.0 mg doses are explicitly classified in the label as initiation and escalation doses — they are not approved maintenance doses on their own.

Above 2.4 mg sits Wegovy HD, a 7.2 mg once-weekly strength the FDA approved in March 2026 and Novo Nordisk launched in the US that April. It is not a new default. The label reserves it for people who have tolerated 2.4 mg for at least four weeks and still need more weight reduction, which makes it a further option rather than the next rung everyone climbs. In its STEP UP trial, 7.2 mg produced about 20.7% average weight loss at 72 weeks against 17.5% at 2.4 mg — a real gain, paid for with more gastrointestinal side effects. The Wegovy dosage guide covers the higher strength in full.

Oral Wegovy tablet dosing schedule (approved December 2025)

In December 2025, the FDA approved an oral version of Wegovy — the first GLP-1 pill approved for weight management in the US. It uses a different escalation ladder than the injectable and is taken once daily on an empty stomach with plain water, followed by a 30-minute wait before eating, drinking anything other than water, or taking other oral medications.

In the OASIS 4 phase III trial, once-daily oral semaglutide 25 mg was associated with a mean weight reduction of approximately 16.6% at 64 weeks. The tablet form offers a needle-free option for patients who cannot or prefer not to self-inject, though supply and insurance coverage were still rolling out in early 2026 — check with your prescriber or pharmacy for current availability.

Semaglutide dosing chart: Ozempic (type 2 diabetes)

Ozempic contains the same active molecule as Wegovy — semaglutide — but it is FDA-approved for glycemic control in adults with type 2 diabetes and for reducing cardiovascular risk in certain patients. Its dose ceiling is lower than Wegovy's, and its escalation schedule differs slightly.

• Weeks 1–4: 0.25 mg once weekly (tolerability dose — not for glucose control)
• Weeks 5–8 (at minimum): 0.5 mg once weekly (first therapeutic dose)
• If additional glycemic control needed: 1.0 mg once weekly (after ≥4 weeks at 0.5 mg)
• If further control needed: 2.0 mg once weekly (after ≥4 weeks at 1.0 mg)

The 2 mg dose was added to the Ozempic label in 2022. Unlike Wegovy, where 2.4 mg is the target for nearly all patients, Ozempic's escalation is driven by blood sugar response — not everyone needs to reach 2 mg. Your prescriber and lab results guide the decision.

One frequently asked question: can a prescriber write an Ozempic prescription for weight loss in a person without diabetes? Technically yes — prescribers can use their clinical judgment — but Wegovy is the FDA-approved tool for that indication, and off-label Ozempic for weight loss has caused significant supply disruptions that affected people with type 2 diabetes who depend on it.

Rybelsus (oral semaglutide) dosing — for diabetes only

Rybelsus is the original oral semaglutide, approved in 2019 for type 2 diabetes. It is a once-daily tablet taken on an empty stomach. Rybelsus is not approved for weight management — that indication belongs to the newer oral Wegovy tablet approved in 2025.

• Days 1–30: 3 mg once daily (initiating dose for tolerability, not for glycemic effect)
• Days 31 onward: 7 mg once daily (first therapeutic dose)
• If more glycemic control is needed after ≥30 days at 7 mg: 14 mg once daily (maximum dose)

Like all oral semaglutide, Rybelsus requires strict administration: swallow with no more than four ounces of plain water, at least 30 minutes before the first food, drink (besides water), or other oral medication of the day. Coffee, tea, or juice taken within that window significantly reduces how much drug is absorbed.

Semaglutide dose in units: how to convert mg to syringe units

The FDA-approved Wegovy and Ozempic pens deliver a fixed milligram dose — you dial the pen, not a syringe. But patients using compounded semaglutide from a vial draw their dose using an insulin syringe, which measures in units. This is where concentration matters enormously, and where dosing errors happen.

The formula is straightforward: divide your prescribed milligram dose by the vial concentration (in mg per mL), then multiply by 100. That gives you units on a standard U-100 insulin syringe.

Conversion table at 5 mg/mL (most common compounded concentration)

• 0.25 mg = 5 units
• 0.5 mg = 10 units
• 1.0 mg = 20 units
• 1.7 mg = 34 units
• 2.4 mg = 48 units

Conversion table at 2.5 mg/mL (less common but in use)

• 0.25 mg = 10 units
• 0.5 mg = 20 units
• 1.0 mg = 40 units
• 1.7 mg = 68 units
• 2.4 mg = 96 units

How many mg is 40 units of semaglutide?

The answer depends entirely on your vial's concentration. At 2.5 mg/mL, 40 units equals 1.0 mg. At 5 mg/mL, 40 units equals 2.0 mg. The same syringe reading can represent two very different doses depending on which vial you have — this is one of the most common sources of accidental under- or overdosing with compounded vials. Never assume the concentration; read the label on your specific vial and confirm with your prescribing provider.

A practical cross-check: your prescriber's instructions should always state both the dose in milligrams and the expected syringe volume in mL or units for your specific vial. If they don't, ask before you inject.

What is the semaglutide maintenance dose — and can it be lower than 2.4 mg?

The standard FDA-approved maintenance dose for Wegovy is 2.4 mg weekly. That's the dose used in the STEP-1 clinical trial, where participants lost a mean of 14.9% of body weight over 68 weeks. But the prescribing information also recognizes 1.7 mg as an alternative maintenance dose for patients who cannot tolerate 2.4 mg.

Some telehealth platforms start patients at lower doses and keep them there longer — partly to manage side effects and partly because of supply constraints and cost. Whether a lower long-term dose is appropriate for any individual patient is a clinical conversation, not a self-directed decision. Some people do achieve meaningful results at doses below 2.4 mg; the pivotal weight-management trials were built around 2.4 mg, so the evidence base for sustained lower doses is thinner.

What to do if you miss a dose

Missing an occasional injection is common and manageable, but the rules differ slightly between Wegovy and Ozempic — and between injectable and oral forms.

Wegovy (injectable) missed dose rule

If it has been fewer than 48 hours since your scheduled injection day, administer the missed dose as soon as you remember. Then return to your regular weekly schedule. If more than 48 hours have passed (meaning the next scheduled dose is approaching), skip the missed dose entirely and resume your normal schedule. Never inject two doses at once to catch up.

Ozempic (injectable) missed dose rule

The window is longer for Ozempic. Per the FDA label, if you miss a dose and it has been five days or fewer since the scheduled date, administer the missed dose. If more than five days have passed, skip it and resume your regular schedule the following week.

Oral Wegovy or Rybelsus (tablet) missed dose rule

For daily tablets, skip the missed dose and take the next tablet the following day at the usual time. Do not double up the next day to compensate.

Missing multiple consecutive doses

If you have missed two or more consecutive weekly injections of Wegovy, the FDA label recommends resuming on your scheduled day or, if needed, reinitiating the dose-escalation schedule — starting from a lower dose — to reduce the gastrointestinal side effects that tend to return when the medication has been out of your system for a while. Your prescriber should guide this restart.

Why the semaglutide dosing schedule for weight loss differs from the diabetes schedule

Both Wegovy and Ozempic use semaglutide and both follow a gradual escalation, but the target doses and clinical goals are different. The Wegovy schedule is designed to reach 2.4 mg as the established efficacious weight-management dose. The Ozempic schedule is titrated based on glycemic response — some patients are well-controlled at 0.5 mg and never need to go higher.

The pens themselves are also physically different. Wegovy pens come pre-loaded in single-use doses matching each escalation step, while Ozempic pens are multi-dose and dose-selectable. You cannot simply substitute one pen for the other and assume the dose is equivalent — both the devices and the prescriptions are product-specific.

Semaglutide dosage in perimenopause and menopause: what the evidence shows

The standard Wegovy escalation schedule is the same regardless of menopausal status — the FDA label does not define a separate protocol for women in perimenopause or postmenopause. But the research is beginning to fill in the picture of how GLP-1 medications perform across reproductive stages.

A 2024 study published in Metabolic Syndrome and Related Disorders examined low-dose semaglutide in menopausal women specifically, looking at body composition changes. A separate analysis from a 2024 issue of the journal Menopause found that postmenopausal women on semaglutide combined with hormone therapy lost approximately 16% of body weight at 12 months, compared to roughly 12% on semaglutide alone — suggesting the hormonal context may affect response. Neither of these findings changes the FDA dose schedule, but they underscore why individual response varies and why the prescriber relationship matters.

Midlife weight changes are tied to the estrogen decline of perimenopause, which shifts fat distribution toward the abdomen and reduces muscle mass. GLP-1 medications address appetite and gastric emptying; they do not replace estrogen. The two are not mutually exclusive, and an increasing number of providers are comfortable discussing both at once.

Where to get a semaglutide prescription

Telehealth platforms have made access to a semaglutide prescriber faster and more affordable than seeing a traditional endocrinologist. Platforms such as Hers and Henry Meds, among others, operate in most US states and can evaluate whether you are a candidate, write the prescription, and monitor your progress remotely.

Compounded semaglutide syringe dosage: current legal status

Through 2023 and into 2024, compounded semaglutide from 503A pharmacies was widely available because semaglutide was listed on the FDA drug shortage list. The FDA removed semaglutide from the shortage list in February 2025, which triggered enforcement deadlines: 503A compounding pharmacies faced an April 22, 2025 deadline, and 503B outsourcing facilities a May 22, 2025 deadline, to wind down compounding of products essentially copying the branded formulations.

As of June 2026, compounded semaglutide may still be legally prepared under narrow circumstances — specifically when a patient has a documented, individualized medical need for a formulation that differs meaningfully from the FDA-approved product (for example, an allergy to an inactive ingredient in Wegovy or Ozempic, or a clinically justified different concentration). The FDA also proposed in April 2026 to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. That proposal was working through the regulatory process as of this writing.

The practical upshot: if you were on compounded semaglutide, your provider should have either transitioned you to a branded pen or documented the specific medical rationale for continued compounding. The unit-conversion math in this page remains relevant if you are on a legitimately prescribed compounded formulation — but the era of broad compounded semaglutide availability has narrowed significantly.